A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT04623775. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT04623775
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 468 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Relatlimab Biological
- Carboplatin Drug
- Cisplatin Drug
- Paclitaxel Drug
- Nab-Paclitaxel Drug
- Pemetrexed Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2021 (Actual)
- Primary completion
- Jan 11, 2024 (Actual)
- Completion
- May 6, 2026 (Actual)
- Last update posted
- Jun 18, 2026
2021 – 2026
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0160 | Duarte | California | 91010 | — |
| Local Institution - 0081 | Orange | California | 92868 | — |
| Local Institution - 0139 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0153 | Jacksonville | Florida | 32204 | — |
| Local Institution - 0011 | Port Saint Lucie | Florida | 34952 | — |
| Local Institution - 0089 | Athens | Georgia | 30607 | — |
| Local Institution - 0121 | Wichita | Kansas | 67214 | — |
| Local Institution - 0159 | Lexington | Kentucky | 40503 | — |
| Local Institution - 0002 | Louisville | Kentucky | 40241 | — |
| Local Institution - 0082 | Scarborough | Maine | 04074 | — |
| Local Institution - 0129 | Omaha | Nebraska | 68130 | — |
| Local Institution - 0152 | Howell Township | New Jersey | 07731 | — |
| Local Institution - 0124 | Johnson City | New York | 13790 | — |
| Local Institution - 0162 | Mineola | New York | 11501 | — |
| Local Institution - 0128 | New York | New York | 10016 | — |
| Local Institution - 0165 | New York | New York | 10021 | — |
| Local Institution - 0097 | The Bronx | New York | 10461 | — |
| Local Institution - 0117 | Durham | North Carolina | 27710 | — |
| Local Institution - 0156 | Cincinnati | Ohio | 45219 | — |
| Local Institution - 0155 | Cleveland | Ohio | 44109 | — |
| Local Institution - 0084 | Lancaster | Pennsylvania | 17604 | — |
| Local Institution - 0147 | Pittsburgh | Pennsylvania | 15212 | — |
| Local Institution - 0148 | Providence | Rhode Island | 02903 | — |
| Local Institution - 0083 | Greenville | South Carolina | 29607 | — |
| Local Institution - 0149 | Dallas | Texas | 75390-9179 | — |
| Local Institution - 0091 | Harlingen | Texas | 78550 | — |
| Local Institution - 0001 | Tyler | Texas | 75701 | — |
| Local Institution - 0092 | Spokane | Washington | 99208 | — |
| Local Institution - 0157 | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04623775, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04623775 live on ClinicalTrials.gov.